Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Promising Developments from OKYO Pharma on Dry Eye Disease and Neuropathic Pain Treatment

OKYO Pharma Ltd

OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 patients in a randomized, double-masked, placebo-controlled study. OK-101, developed using a membrane-anchored-peptide technology, is a novel long-acting drug candidate designed to treat dry eye disease. It has shown anti-inflammatory and pain-reducing efficacy in mouse models of dry eye disease and corneal neuropathic pain. Jacobs highlighted that the findings include a statistically significant and durable reduction in ocular pain and a statistically significant improvement in Tear Film Break-Up Time throughout the study, which is a clinically important endpoint. Additionally, multiple symptomatic improvements were observed through both data obtained from patient clinic visits and daily symptom diaries. Jacob explained that OK-101 targets a receptor called Chemerin 23, present on both immune and nerve cells, including those in the spinal cord and ocular nerves. Preclinical animal studies indicated that OK-101 could reduce neuropathic pain, which can be particularly severe and debilitating in affected patients. The company is preparing to launch a Phase II trial for OK-101 specifically targeting neuropathic corneal pain. This trial will be a placebo-controlled, randomized study involving 48 patients diagnosed with ocular nerve damage through confocal microscopy, with top-line data anticipated by mid-2025.The significance of this development is underscored by the lack of FDA-approved treatments for neuropathic corneal pain, a condition recognised by the National Organization of Rare Diseases. The upcoming trial aims to fill this therapeutic gap, potentially offering relief to patients suffering from this excruciating condition. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

June 26, 2024 10:29 AM Eastern Daylight Time

Video

DentalPlans.com: Empowering Families To Live Healthier Lives Through Affordable And Flexible Dental Savings Plans

DentalPlans.com

By Mangeet Kaur Bouns, Benzinga Oral health plays a vital role in our daily lives, impacting our ability to speak, smile and eat comfortably. Maintaining good dental hygiene not only enhances our appearance and self-esteem but also significantly influences overall well-being. Research has linked poor oral health to serious health issues such as heart disease, respiratory infections, stroke, diabetes and certain cancers. Finding affordable dental care is crucial for families. Traditional insurance has long been the standard, but dental savings plans are a flexible, cost-effective alternative. DentalPlans.com, a leader in dental savings plans, has transformed access to dental care in the U.S. over the past 25 years, making it easier for families to access affordable dental care without sacrificing quality. Understanding The Differences: Traditional Insurance Vs. Dental Savings Plans Traditional dental insurance typically involves paying monthly premiums in exchange for coverage that includes a percentage of costs for various services. These plans often come with annual spending caps, deductibles and waiting periods, which can limit immediate access to certain treatments. Additionally, there may be exclusions for pre-existing conditions and network restrictions that confine patients to a specific group of providers. In contrast, the dental savings plans available on DentalPlans.com do away with these limitations. By offering membership-based access to discounted rates from a vast network of over 140,000 dentists and specialists, these plans provide substantial savings without deductibles or annual limits. Plan members can receive care for existing dental conditions and enjoy flexibility in choosing their providers nationwide. Simply show your membership card at the dentist to receive savings. No Limits, No Restrictions: A Key Advantage One of traditional insurance's most significant drawbacks is the cap on coverage. Annual limits for a PPO plan are typically between $1,000 and $1,500 and can be quickly exhausted, especially when you need major dental procedures like root canals or crowns, which can cost between $750 and $2,000 per tooth. Once these limits are reached, patients must cover the remaining costs out-of-pocket while continuing to pay their insurance premiums. The dental savings plans on DentalPlans.com eliminate these restrictions, allowing plan members to access necessary dental care without worrying about annual limits. This includes treatments for existing dental conditions. Families can see as many participating providers as needed–for any number of reasons – including virtually all treatments, from cleanings to braces to root canals and dental implants. Extensive Network With Flexibility And Inclusivity The dental savings plans on DentalPlans.com are accepted by over 140,000 dentists and specialists nationwide, including pediatric dentists, orthodontists and endodontists, so choosing a dental savings plan doesn’t sacrifice network size. This broad network ensures that all family dental needs are met. The company offers more than 25 dental plans from top healthcare brands like Cigna, Aetna, Careington, United Concordia and Dentegra, ensuring your family will find a plan that fits its needs and budget. Dental savings plans also provide the flexibility to switch plans. Whether your family needs preventive care, braces for a child, or a root canal for an adult, DentalPlans.com allows for a seamless transition between plans, maximizing savings and maintaining continuous care. Ease Of Use And Significant Savings DentalPlans.com simplifies getting dental care with dental savings plans, which are easy to use and activate quickly (within 1-3 business days of signup). There is no paperwork to navigate and plan members can immediately save with reduced rates at the time of treatment. This straightforward approach not only saves time but also provides peace of mind when it comes to managing dental expenses. Dental savings plan members report saving an average of 50%* on their dental care, highlighting the cost-effectiveness of dental savings plans. Whether you're traveling and need to visit a dentist or simply require regular dental services, DentalPlans.com ensures continuous, affordable care. DentalPlans.com Leads The Way In Providing Quality, Affordable Dental Care For Families While traditional dental insurance has its benefits, the dental savings plans from DentalPlans.com offer a compelling alternative or complement with distinct advantages, such as no annual limits, no restrictions on existing dental conditions, an extensive network of providers, flexibility, ease of use and significant savings. The company's innovative and customer-focused approach continues to drive it toward achieving dental care equality, ensuring that everyone has the opportunity to access high-quality dental services. As DentalPlans.com celebrates its 25th anniversary, its commitment to making dental care accessible and affordable for everyone remains unwavering. Visit DentalPlans.com to learn more about dental savings plans and see how much you can save today. Featured photo by MonkeyBusinessImages at Shutterstock DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. *Discount Health Program consumer & provider surveys indicate average savings of 50%. Savings may vary by provider, location and plan. Sample savings are based on zip code 43614, actual costs and savings may vary service and geographical area. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

June 26, 2024 08:45 AM Eastern Daylight Time

Image

BenevolentAI and AstraZeneca collaborate on new lupus target

BenevolentAI

BenevolentAI chief scientific officer Dr Anne Phelan speaks to Proactive's Stephen Gunnion about the addition of a novel systemic lupus erythematosus (SLE) target to AstraZeneca's discovery portfolio. Phelan discussed the collaboration between BenevolentAI and AstraZeneca, which began in 2019 focusing on idiopathic pulmonary fibrosis and chronic kidney disease and later expanded to include heart failure and lupus. She highlighted the benefits of this collaboration, stating, "We can really leverage the power of the interconnectivity of the data foundations to pull through potential target hypotheses irrespective of the disease." Phelan explained how BenevolentAI's data-driven approach, combined with AstraZeneca's disease expertise, facilitates the identification and validation of new therapeutic targets. She also provided insights into lupus, describing it as a debilitating autoimmune disease where the body's immune system attacks its own tissues, leading to chronic fatigue and damage to vital organs. The BenevolentAI platform's ability to handle complex data and generate explainable hypotheses is pivotal in identifying new therapeutic targets for such complex diseases. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

June 26, 2024 08:01 AM Eastern Daylight Time

Video

atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression

atai Life Sciences

Atai Life Sciences co-founder and co-CEO Florian Brand discussed initial results from Beckley Psytech’s phase 1 trial of its patent-protected psilocin ELE-101 in patients with major depressive disorder. Brand explained that ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin, developed for depression treatment. The IV formulation aims to reduce treatment duration to two hours, compared to the longer sessions required by traditional psilocybin and LSD treatments. Phase one trials in healthy participants showed that ELE-101 was well tolerated with no serious safety concerns and had a predictable pharmacokinetic profile, supporting dose selection for phase two trials. Brand highlighted the commencement of phase 2 trials with the first patient already dosed. This study involves 6 to 12 patients, with data expected in the second half of this year. atai Life Sciences is optimistic about the shorter treatment duration, potentially making it more convenient for patients and less burdensome for the healthcare system. Additionally, Brand mentioned their involvement with Compass Pathways, which is developing psilocybin therapy, and noted the importance of the two-hour treatment paradigm established by the intranasal esketamine spray, Spravato. This paradigm could be leveraged for their other compounds, such as BPL-003 and DMT, also being developed for depression treatment. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

June 26, 2024 06:09 AM Eastern Daylight Time

Video

Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs

Superlab Suisse

For life sciences and biotech companies, access to affordable dedicated lab spaces is hard to come by. Labs are prohibitively expensive to build and operate, posing significant financial barriers to innovation and research. A cutting-edge new alternative is being offered by Superlab Suisse, a leading provider of innovative laboratory and research spaces that today announces the grand opening of its newest facility in Basel. With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland. Opening in July 2024, following the success of the Lausanne location supported by Biopôle Lausanne and InnoVaud, the expansion marks a significant milestone in Superlab Suisse's mission to provide research infrastructure to Switzerland's dynamic life sciences sector. Forging ahead with its successful partnership with Swiss Prime Site, Superlab Suisse is set to open the door for huge commercial opportunities in the ideally suited location of Basel, a booming biotechnology hub and home to over 700 companies including pharmaceutical giants like Novartis and Roche. The new facility, nestled within the bustling Stücki Park with neighbours like Tech Park Basel, Lonza, Medartis, NBE, and Boehringer Ingelheim, offers ready-to-use laboratory spaces equipped with the latest technology and essential operational support services, allowing teams to channel their resources into scientific research rather than lab operations. Spanning over 4770 square metres, it promises to be a nucleus of scientific collaboration and breakthrough, redefining laboratory services in Basel. "We are thrilled to bring Superlab Suisse's innovative platform to Basel, the city of Pharma," says Xi Zhang, CEO of Superlab Suisse. “Our holistic solution frees scientists from operations headaches, so they can save time and focus on science. We service, you discover”. Life sciences and biotech companies have until now lacked the widely accepted lab solutions that have benefitted industries such as tech and finance. Universities have typically been the only viable option, with lab construction and operation requiring significant upfront investments — costs which redirect attention away from research and delay progress in getting products to market. Superlab Suisse's serviced BSL1 and BSL2 labs provide a new industry standard of lab solution. Users in one location such as Basel also gain access to facilities in Lausanne and other locations. By delivering ready to move in lab solutions for life science companies of all sizes, including startups, scale-ups, and corporates, Superlab Suisse eliminates the hurdles of lab construction and operation. One of the first companies to secure their space at the opening is Skyhawk Therapeutics, which has recently announced a research collaboration with Ipsen focusing on RNA targeting in rare neurological diseases. In addition to the Basel location, Superlab Suisse continues its commitment to innovation with plans for a third site in Zurich Schlieren. This new facility, scheduled to open in March 2025, will cater to the diverse needs of start-ups, spin-offs, and established companies in the life sciences sector, further solidifying Superlab Suisse's position as a leader in laboratory-as-a-service solutions. This one-stop solution not only solves the true problems of life science companies but also attracts like-minded innovators to meet and collaborate. Superlab is expanding this year to more cities in Europe, the US, and Asia, embodying a borderless lab concept because life science benefits humanity as a whole. Dr. Rajwinder Lehal, CEO of biotech business Cellestia commented: “Superlab is exactly the place which the scientific community needs, where we can concentrate on our work without being distracted by construction or operation. Superlab provided us with state of the art infrastructure and equipment that we needed to hit the ground running from day 1.” Emmanuel Savioz, CEO & Chairman, Tigen Pharma commented: “Superlab is a great place to work in a vibrant scientific community. Our team at Tigen can focus on growth, supported by state-of-the-art facilities, latest equipment and a competent and fun Superlab team to support on-site”. About Superlab Suisse AG Superlab Suisse AG offers innovative laboratory solutions through its "Lab as a Service" business concept. With state-of-the-art facilities, professional services, and financing support, Superlab Suisse empowers companies in the biotech, pharma, and medtech sectors to focus on research and innovation. About Swiss Prime Site AG Swiss Prime Site is the largest real estate company in Switzerland and one of the leading commercial property companies in Europe. The real estate portfolio spanning across densely populated areas is valued at approximately CHF 26 billion and includes own properties – with about CHF13 billion commercial properties and development projects – as well as ones managed on behalf of third parties with about CHF 13 billion AuMs invested in residential and commercial buildings. Contact Details Superlab Suisse Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://superlabsuisse.com/

June 25, 2024 07:00 AM Eastern Daylight Time

Image

Botanical Remedies LLC Introduces Enhanced Kratom Feature for Customized Potency

Rev Up Marketers

Botanical Remedies LLC, a leading provider of premium, lab-tested kratom products, is proud to announce the launch of its innovative Enhanced Kratom Feature, designed to offer customers a tailored experience with customized potency. This new feature marks a significant advancement in the kratom industry, underscoring the company's commitment to quality, safety, and customer satisfaction. The Enhanced Kratom Feature allows customers to select kratom products with customized potency levels, catering to individual preferences and needs. This feature leverages advanced processing techniques and rigorous lab testing to ensure each product meets precise potency specifications. By offering customizable options, it empowers users to fine-tune their kratom experience for optimal wellness benefits. Botanical Remedies LLC is dedicated to providing the highest-quality kratom products. The company meticulously sources its kratom from reputable farmers and suppliers who prioritize ethical practices and sustainability. Each batch of kratom undergoes rigorous third-party testing to verify its purity, potency, and safety. This comprehensive testing process ensures that products are free from contaminants, heavy metals, and adulterants, offering customers peace of mind and a superior product. The Enhanced Kratom Feature is available across Botanical Remedies LLC’s extensive range of kratom strains, including popular varieties such as Green Maeng Da, Gold Vein, and Hippie Dip. Customers can now choose their preferred strain and customize the potency to match their specific requirements. Whether seeking relaxation, focus, or energy, users can select the precise potency that best suits their needs. Ordering from Botanical Remedies LLC, is a seamless process. Customers can browse the extensive collection of premium kratom products on the company’s website, select their preferred strain and potency, and proceed to a secure checkout. The company prioritizes the safety of customer information, ensuring a secure transaction process. The company ensures prompt and discreet delivery of orders through fast and discreet shipping. Botanical Remedies LLC prides itself on providing exceptional customer support. The knowledgeable and friendly team is available to assist with any questions or concerns, offering guidance on product selection and usage. The company is committed to ensuring customer satisfaction and building long-lasting relationships with its valued clients. Confident in the quality of its products, Botanical Remedies LLC offers a satisfaction guarantee. If customers are not entirely pleased with their purchase, the company’s customer service team will work diligently to resolve any issues and ensure complete satisfaction. Customers who choose Botanical Remedies LLC join a thriving community of kratom enthusiasts. The company engages with its community through social media and newsletters, providing updates on new products, exclusive offers, and kratom-related information. About Botanical Remedies LLC is a veteran-owned company dedicated to providing premium, lab-tested kratom products. The company combines its dedication to quality with a profound respect for ethical practices, guaranteeing the sustainable sourcing and rigorous testing of all products. With a focus on customer satisfaction, it continues to set the standard in the kratom industry. For more information about Botanical Remedies LLC and the Enhanced Kratom Feature, please visit www.botanicalremediesllc.com. Contact Details Botanical Remedies LLC Shelly Hughes +1 305-393-4847 support@bremediesllc.com Company Website http://www.botanicalremediesllc.com/

June 24, 2024 10:13 AM Eastern Daylight Time

Image

Select Sector SPDR ETFs: A Focused Approach for Sector-Specific Portfolio Management

Select Sector SPDR

In the ever-changing landscape of the financial markets, Select Sector SPDR ETFs present a method for investors looking to engage in sector-specific investments. By breaking down the S&P 500 into distinct sectors, these ETFs provide a pathway for both individual and institutional investors to craft more targeted and strategic investment portfolios. The Select Sector SPDR ETFs encompass a range of sectors, each represented by a dedicated ETF. This structure allows investors to focus their investments on specific areas of the economy, depending on their investment objectives, risk tolerance, and market outlook. Overview of Select Sector SPDR ETFs: Communication Services Select Sector SPDR Fund (XLC): Focuses on telecommunications and media companies. Consumer Discretionary Select Sector SPDR Fund (XLY): Targets companies focused on non-essential goods and services such as luxury items, travel, and leisure. Consumer Staples Select Sector SPDR Fund (XLP): Concentrates on essential consumer goods and services like food, clothing, and personal products. Energy Select Sector SPDR Fund (XLE): Dedicated to the energy sector, focused on oil and natural gas. Financials Select Sector SPDR Fund (XLF): Encompasses banking, investment, and insurance industries. Health Care Select Sector SPDR Fund (XLV): Focuses on pharmaceuticals, healthcare equipment, and services. Industrials Select Sector SPDR Fund (XLI): Includes manufacturing, construction, and logistics firms. Materials Select Sector SPDR Fund (XLB): Covers the chemicals, construction materials, and packaging industries. Real Estate Select Sector SPDR Fund (XLRE): Targets commercial real estate services and REITs. Technology Select Sector SPDR Fund (XLK): Concentrates on the information technology, semiconductor, and electronics sectors. Utilities Select Sector SPDR Fund (XLU): Dedicated to electric and gas utility companies. By offering a straightforward and transparent approach to investing in specific sectors, Select Sector SPDR ETFs enable investors to adapt their investment strategies in response to changing market conditions. The Select Sector SPDR ETFs offer a focused approach to investment, allowing for detailed sector analysis and strategic portfolio management. As the financial landscape continues to evolve, these ETFs provide a valuable tool for investors looking to refine their investment strategies through sector-specific allocations. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007597 EXP 8/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

June 24, 2024 05:00 AM Eastern Daylight Time

The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes

Kadimastem

Kadimastem Ltd. (TASE: KDST), announces positive results of its leading diabetes product jointly developed with iTolerance Inc. The results were presented at the 84th scientific conference of the American Diabetes Association (ADA), in a late-breaking session. The product was evaluated by at the DRI, The Fast Track Center for Testing at the DRI Cell Transplant Center where it was designated to be a “novel combination of tolerance-inducing agent and human stem cell-derived islets demonstrates functional insulin release and disease reversal in a model of diabetes.” Link to quote. The recognition of the scientific progress of the treatment, which combines immune modulator microgel material (a substance that eliminates the need for chronic systemic immune suppression) and insulin-producing islet cells derived from human stem cells, as an innovative treatment intended for the treatment of type 1 diabetes, was given by the world's largest diabetes research institute at the University of Miami (Florida) School of Medicine (DRI). The experts at DRI presented product compatibility, safety and efficacy to the conference attendees, concluding that combination of the engineered iTOL-100 microgel material developed by iTolerance and the pancreatic cells - IsletRx developed by Kadimastem - can effectively restore normoglycemia (a state of glycemic balance like that of a healthy person) in a diabetes animal model. Dr. Giacomo Lanzoni, PhD, program leader at the DRI, stated, "Our observations highlight the transformative potential of combining stem cell-derived islets with an immunomodulatory microgel. This approach could enable transplantation across the allogeneic barrier, offering a scalable and sustainable solution for T1D, and could enhance the safety and long-term efficacy of islet cell transplantation.” Dr. Camillo Ricordi, MD, Director of the Cell Transplant Center and Director Emeritus at the Diabetes Research Institute, commented: “The Fast Track Center for Testing at the DRI Cell Transplant Center continues to serve as a key shared resource to validate emerging technologies towards a cure for diabetes. We hope to continue to be of assistance towards the identification of reliable and potentially unlimited stem cell-derived islet sources for transplantation, which may one day be able to replace the limited availability of pancreas-derived islets from multiorgan donors, when life-long recipient immunosuppression will no longer be required.” The study's key findings indicate that this combination therapy reverses diabetes and preserves the functional integrity of the transplanted stem cell-derived islets. Key Highlights: -IsletRx, a preparation of Human Stem Cell-Derived Islets developed by Kadimastem, Ltd., is a scalable and virtually unlimited source of insulin-producing cells, and could address the critical shortage of donor islets for transplantation. -iTOL-100, an immunomodulatory microgel developed by iTolerance, Inc., designed to eliminate the need for chronic systemic immunosuppression and shown to induce local immune acceptance of transplanted islets, was found to be compatible with stem cell-derived islets. -Implantation in a Retrievable Site: The transplantation procedure is performed in a retrievable site, ensuring the possibility of graft retrieval through a minimally invasive surgery, if needed. -Successful Reversal of Diabetes: The study reports reversal of disease in a chemically induced model of diabetes, with comparable efficacy of IsletRx in the presence or absence of iTOL-100, indicating a lack of toxicity from the microgel. Additional Comments: Prof. Michel Revel, Chief Scientist of Kadimastem: "Our collaboration with iTolerance opens an innovative and world-first avenue for transplanting pancreatic island cells into diabetics without the need for full suppression of the immune system, which is required today in organ transplants. Prof. Revel emphasized, "Our company produces high-quality pancreatic islet cells. The joint data collected by us prove the possibility of combining our cells with the material that locally prevents the rejection of the implant developed by our project partner iTolerance. The successfully completed an Interact meeting with the FDA, and the two companies are moving together to the pre-IND submission stage." Dr. Anthony Japour, CEO of iTolerance, Inc., commented, “iTolerance is pleased to co-sponsor the project at the Diabetes Research Institute toward a functional cure of T1D through the combination of human stem cell-derived insulin producing islet cells together with our iTOL-100 proprietary immunomodulator. Removing the need for life-long toxic immunosuppressive agents in islet transplantation is a common goal among those working toward a cure for T1D through transplantation without immunosuppression.” About Kadimastem Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Social Media: LinkedIn, Twitter, Facebook About iTolerance, Inc. iTolerance is an early-stage privately-held regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic pancreatic islets and stem cells that have the potential to cure diseases. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com. About the Diabetes Research Institute (DRI) The Diabetes Research Institute at the University of Miami Miller School of Medicine is a recognized world leader in cure-focused research. The DRI is committed to developing and rapidly applying innovative strategies to restore natural insulin production and normalize blood sugar levels without imposing other risks. For more information, please visit https://diabetesresearch.org/ Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. Kadimastem was founded in 2009 based on patent protected technology that was developed at Prof. Michel Revel’s laboratory at the Weizmann Institute of Science. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Ltd. Asaf Shiloni CEO +972 73-797-1613 s.bazak@kadimastem.com iTolerance Inc. Susan Roberts +1 202-779-0929 sr@roberts-communications.com Company Website https://www.kadimastem.com/

June 23, 2024 07:00 AM Eastern Daylight Time

Image

Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Benzinga

By Meg Flippin, Benzinga When it comes to screening for colorectal cancer, Mainz Biomed NV (NASDAQ: MYNZ) and Exact Sciences Corp. (NASDAQ: EXAS) have a lot in common. Both are overhauling the screening market for a cancer that kills 50,000 people each year. And both are doing it without an invasive test that requires hours of uncomfortable prep. Exact Sciences, which makes Cologuard and Mainz Biomed, which makes ColoAlert, are trailblazing with their at-home cancer screening tests. Cologuard in the U.S. and ColoAlert in Europe. Take ColoAlert for starters. It spots bleeding and non-bleeding tumors through tumor DNA analysis, offering what the company says is a better early detection than fecal occult blood tests. That’s important since almost all colorectal cancers develop from polyps that grow over time. The longer the polyps are present, the higher the risk of them becoming cancerous, which is why early screening has the potential to dramatically impact treatment and prevention. Caught early, the survival rate after five years is 90% for colorectal cancer. Exact Sciences’ Cologuard looks for colorectal neoplasia-associated DNA markers and for the presence of occult hemoglobin in human stool. It, too, says its screening technology is better at detecting colorectal cancer than blood tests. Similar But Different The companies both boast high accuracy rates and customer satisfaction. But that is where the similarities end. Exact Sciences dwarfs Mainz Biomed in size and sales, sporting a market cap of $7 billion to Mainz Biomed’s $12.6 million as of this writing. Exact Sciences stock, which trades at around $42 a share, has already had a runup, while Mainz Biomed, which is under $1.00 a share, is just starting out. That might not be forever, which could position Mainz to follow a similar trajectory to Exact Sciences and other diagnostics companies specializing in the detection of early-stage cancers. Exact Sciences launched Cologuard in 2014, becoming the first DNA test for colorectal cancer in the U.S. Since then, it has expanded into other cancers and its stock and business have taken off. Mainz has been in the market since 2018 and sales have been growing at double digits since then. Revenue for ColoAlert increased 69% year-over-year in 2023 and more growth is expected this year and beyond. ColoAlert Coming To The U.S. Mainz Biomed has already made a name for itself in Europe and is gearing up to bring ColoAlert to the U.S. ColoAlert is currently under evaluation by the Food and Drug Administration for use in the U.S. as part of its ReconAAsense clinical study of about 15,000 subjects from 150 sites across the United States. The results of the study, which is pivotal for FDA approval, are expected next year. Once approved, MYNZ says it plans to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country. If it does get the nod from the FDA, it could prove to be a catalyst for the company’s growth. It shouldn’t prove difficult given ColoAlert’s accuracy and ease of use. The company says ColoAlert detects 85% of colorectal cancer cases, often in the very early stages of the disease. A recent multicentric study of 566 patients simultaneously using the occult blood test, M2-PK test and ColoAlert, found ColoAlert, with a sensitivity of 85% and a specificity of 92%, was the most accurate test result among the non-invasive screening methods. The company plans to engage in further testing to validate the effectiveness of its screening over what’s already available in the market. “Combined DNA stool assay represents a reliable assay for detecting colorectal cancer, sufficient to be recommended as a supplement to colonoscopy screening,” the study researchers reported. Big Opportunity On The Horizon Then there is the market opportunity. As it stands, 37 million people in the U.S. get screened for rectal cancer each year. That could increase to 52 million per year within ten years as the population ages. In the United States there are 112 million people 50+, which is expected to increase to 157 million in the next decade. Of the U.S. population between 50 and 75, about 40% have never been screened. While the common practice is to start the screening at 50, the Food and Drug Administration says screening should start at age 45 and be conducted every three years. If that guidance is followed, it presents an even bigger opportunity for ColoAlert. All told, Mainz pegs the U.S. opportunity at $4 billion and the European market opportunity at $6 billion. Colorectal cancer is deadly but it doesn’t have to be. Companies like Exact Sciences and Mainz Biomed are turning the market on its head with their at-home screening tests. While Exact Sciences dwarfs Mainz in size, Mainz has a lot of potential, especially if it gets approval to sell its test in the U.S. With that coming down the pike, Mainz is a story worth keeping an eye on. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 21, 2024 08:45 AM Eastern Daylight Time

Image

1 ... 21 22 23 24 25 ... 310